These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34749255)

  • 1. A new fluorescence-based method for rapid and specific quantification of rotigotine in chitosan nanoparticles.
    Saha P; Pandey MM
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Feb; 267(Pt 2):120555. PubMed ID: 34749255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency.
    Saha P; Singh P; Kathuria H; Chitkara D; Pandey MM
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DoE-based validation of a HPLC-UV method for quantification of rotigotine nanocrystals: Application to in vitro dissolution and ex vivo nasal permeation studies.
    Saha P; Pandey MM
    Electrophoresis; 2022 Feb; 43(4):590-600. PubMed ID: 34783375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A liquid crystal in situ gel based on rotigotine for the treatment of Parkinson's disease.
    Wu X; Cheng D; Lu Y; Rong R; Kong Y; Wang X; Niu B
    Drug Deliv Transl Res; 2024 Apr; 14(4):1048-1062. PubMed ID: 37875660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
    Bhattamisra SK; Shak AT; Xi LW; Safian NH; Choudhury H; Lim WM; Shahzad N; Alhakamy NA; Anwer MK; Radhakrishnan AK; Md S
    Int J Pharm; 2020 Apr; 579():119148. PubMed ID: 32084576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotigotine: A Review of Analytical Methods for the Raw Material, Pharmaceutical Formulations, and Its Impurities.
    Mendes TC; Pinto EC; Cabral LM; de Sousa VP
    J AOAC Int; 2021 Jun; 104(3):592-604. PubMed ID: 33276374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
    Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
    Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence spectroscopy method for estimation of Ivabradine in bulk and the tablet dosage form.
    Tailor PM; Naik K
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120330. PubMed ID: 34481253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status and Challenges in Rotigotine Delivery.
    Md S; Karim S; Saker SR; Gie OA; Hooi LC; Yee PH; Kang AWC; Zhe CK; Ian N; Aldawsari HM; Hosny KM; Alhakamy NA
    Curr Pharm Des; 2020; 26(19):2222-2232. PubMed ID: 32175832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease.
    Mohamed S; Riva R; Contin M
    Biomed Chromatogr; 2017 Sep; 31(9):. PubMed ID: 28168729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
    Moretti DV; Binetti G; Zanetti O; Frisoni GB
    Neuropharmacology; 2014 Oct; 85():284-9. PubMed ID: 24915072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
    Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
    Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.